NVIDIA Announces BioNeMo Agent Toolkit — Tools for Agents to Accelerate Scientific Discovery

About this update from Nvidia Corporation

NVIDIA BioNeMo Agent Toolkit News Summary: SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- BIO -- NVIDIA today announced NVIDIA BioNeMo Agent Toolkit, which provides domain-specific tools and skills for the agentic life sciences era. Including more than a decade’s worth of NVIDIA life sciences libraries, tools and open models, the toolkit enables AI agents, scientists and labs to work together by gathering evidence, reasoning across findings, running computational experiments and recommending the next best steps to accelerate discovery. It gives any agent or AI platform — from general-purpose assistants to specialized scientific agents, software platforms and in-house biopharma systems — the tools needed to synthesize and summarize scientific knowledge, call models, evaluate results, reason and execute next actions. The toolkit includes NVIDIA BioNeMo™ and is powered by NVIDIA NIM™ microservices, NVIDIA Parabricks®, NVIDIA NeMo™ and NVIDIA Nemotron™ technologies, along with accelerated computing and skills — providing an open and trusted foundation for agentic life sciences. More than 50 leading companies are already using it to advance scientific discovery, tapping into agent-callable skills for tasks including protein structure prediction, molecular docking, generative chemistry, genomic analysis, protein design and biomarker discovery. “Frontier models are the brains. BioNeMo is the scientific toolbox. Together, they give AI agents the skills of a PhD research assistant and the speed of a supercomputer,” said Jensen Huang, founder and CEO of NVIDIA. “For the first time, researchers can build AI agents that understand scientific knowledge, use scientific tools and execute scientific workflows. This is a new way to do science — one that can dramatically accelerate discovery across biology, chemistry, genomics and medicine.” Open model and research organizations — including the Arc Institute, Open Molecular Software Foundation and the University of Washington’s Institute for Protein Design (IPD) — are working with NVIDIA to use BioNeMo to advance frontier models and make them more accessible through agent-ready workflows. The IPD collaboration has accelerated runtimes for state-of-the-art biodesign models like RosettaFold3, resulting in 2x faster performance than the prior-generation model, and many additional applications to accelerate protein design effort...

View stock analysis, news, and events for Nvidia Corporation